Business

The UK’s psychedelic sector is moving into a more commercially significant phase, with late-stage clinical programmes, pharmaceutical investment and changes...

Emyria (ASX: EMD) has cleared a key operational bottleneck across its Perth and Queensland psychedelic-assisted therapy operations, with therapist availability...

For psychedelic investors, finding the next breakthrough company is the difficult part. Neo Kuma Ventures appears to have made at...

Emyria is building a second business behind its growing mental health operation: a drug discovery and development programme focused on...

Australia's psychedelic medicine industry has crossed the regulatory threshold. Since 1 July 2023, specifically authorised psychiatrists have been able to...

Definium Therapeutics has reported positive Phase III results for its LSD-based medicine DT120 in generalised anxiety disorder, giving the company...

As psychedelic-assisted therapy moves from research into clinical practice in Australia, the organisations building the infrastructure around the sector are...

The next phase of psychedelic drug development may not involve psychedelics in the traditional sense. As researchers and pharmaceutical companies...

Institutional investors are returning to psychedelic medicine in force, with the sector raising more than US$1 billion in a single...

For much of the past decade, Australia's medicinal cannabis industry has been defined by domestic growth. Companies raced to expand...